How do start-ups seek to cooperate with large multinational pharmaceutical companies?

Source: as early as four years ago, pharmaceutical geography 2018-03-15, the author was very optimistic about zaiding pharmaceutical, a start-up biotech pharmaceutical enterprise In addition to the rich resume and world-class management team of its leader Du Ying, zaiding pharmaceutical's open innovation and R & D mode is a rare innovation mode in the traditional new drug R & D environment of that year Zaiding pharmaceutical successfully landed on NASDAQ in September last year after receiving support from several top global investment institutions including Qiming venture capital fund, kaipenghuaying China fund and Sequoia Capital Decoding zaiding medicine lies in its open innovation R & D mode, which is called "license in + cro" Zaiding pharmaceutical has established a comprehensive product line through global R & D and regional development, internal R & D and external licensing around tumor, autoimmune, infectious diseases and other major fields At the same time, it cooperates with cro companies such as Wuxi Wuxi Pharmaceutical Co., Ltd and tiger Pharmaceutical Co., Ltd to strictly control the key links of the project and ensure the quality and standard of the test data reach the international level Table: at present, multiple new drugs have entered the middle and late stage of clinical research and development in the open innovation R & D mode of zaiding pharmaceutical, as shown in the figure below Zl2401, a new drug under research, is zaiding medicine from paratek It is obtained by pharmaceuticals for the treatment of acute bacterial skin / skin structure infection, community-acquired bacterial pneumonia and urinary tract infection; the new drug zl2301 under research is alanine britannib tablet licensed from Bristol Myers Squibb patent; zl2306 is obtained in cooperation with tesaro, a pharmaceutical company of the United States, for the treatment of ovarian cancer, and will soon start phase III clinical trials Figure: as can be seen from the R & D pipeline of zaiding pharmaceutical, patent authorization is an important means for zaiding pharmaceutical to enrich the R & D pipeline The so-called patent authorization means that, according to the license agreement, the original research company will usually obtain the pre payment for technology transfer and the stage achievement payment for clinical development, drug declaration and industrialization, which is often referred to as the "milestone" payment, and share the R & D risk with the introduced company If the product is successfully listed, the original research company will also obtain the agreed sales share Table: the re Ding pharmaceutical patent licensing project further decodes the operation mode of re Ding pharmaceutical patent licensing, which is mainly to seek R & D cooperation with large multinational pharmaceutical enterprises through patent use right transfer with the financial support of the world's leading medical venture capital institutions Especially in the choice of patent supplier, the transfer of patent right and the evaluation of patent value, zaiding pharmaceutical's practice is worth learning from The choice of patent supplier: different from other biomedical technology enterprises in China who choose universities or scientific research institutes as the main source of patent technology, zaiding pharmaceutical mainly chooses multinational pharmaceutical enterprises as the patent supplier The reason is that on the one hand, zaiding pharmaceutical has a leading team with global senior management experience, standing high and far, and is committed to the corporate mission of building a global leading drug R & D base On the other hand, as early as in the Hehuang period, Du Ying established strategic cooperation with AstraZeneca, Johnson & Johnson, Lilly, Merck and other multinational giants Transfer mode of patent use right: from the perspective of the practice of the patent licensing project of zaiding pharmaceutical, the transfer mode of signing the patent technology transfer contract of zaiding pharmaceutical mainly includes exclusive use right and exclusive use right Exclusive use right refers to the exclusive use right of the licensed technology within the specified territory, and the seller cannot use the technology and sell the products produced by the technology within the period specified in the contract, such as Korean American medicine and Sanofi patent licensing project Exclusive use right means that the seller only grants the use of the technology within the time and territory specified in the contract, but the Seller reserves the right to use and the right to sell the product, and no longer transfers the technology to a third party, such as Bristol Myers Squibb patent licensing project Patent value evaluation: the complexity of patent technology itself leads to the complexity of its own transfer process At the same time, technology maturity, social needs, use costs, risk frequency, etc also directly affect the difficulty of its transfer The senior research team of zaiding pharmaceutical evaluates the value of each patent technology transfer Figure: operation mode of zaiding pharmaceutical patent authorization